WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
WuXi Biologics (2269.HK) has received a Platinum Award from The Asset ESG Corporate Awards for the fourth consecutive year. This prestigious honor recognizes the company's commitment to sustainable practices and its effective approach to driving innovation and efficiency through green technology.
The Asset evaluates companies on various ESG metrics, including corporate governance, sustainability financing, supplier codes of conduct, energy consumption, GHG emissions, and waste and water management. WuXi Biologics is the only healthcare industry company among this year's winners.
The company has made significant progress in pursuing sustainable development and socially responsible policies, aligning with the United Nations Sustainable Development Goals. WuXi Biologics is a signatory to the UN Global Compact and the Science Based Targets initiative (SBTi) commitment letter.
WuXi Biologics' ESG efforts have been recognized by major rating agencies, receiving accolades such as an 'AAA' rating from MSCI ESG Ratings, a Platinum Medal from EcoVadis, and inclusion in various prestigious ESG indexes.
WuXi Biologics (2269.HK) ha ricevuto un Premio Platinum dagli Asset ESG Corporate Awards per il quarto anno consecutivo. Questo onore prestigioso riconosce l'impegno dell'azienda verso pratiche sostenibili e il suo approccio efficace nel promuovere innovazione ed efficienza attraverso la tecnologia verde.
The Asset valuta le aziende su vari metriche ESG, inclusi governance aziendale, finanziamento sostenibile, codici di comportamento dei fornitori, consumo energetico, emissioni di gas serra e gestione dei rifiuti e dell'acqua. WuXi Biologics è l'unica azienda del settore sanitario tra i vincitori di quest'anno.
L'azienda ha fatto significativi progressi nel perseguire uno sviluppo sostenibile e politiche socialmente responsabili, allineandosi con i Goal di Sviluppo Sostenibile delle Nazioni Unite. WuXi Biologics è firmataria del Global Compact delle Nazioni Unite e della lettera di impegno dell'iniziativa Science Based Targets (SBTi).
Gli sforzi ESG di WuXi Biologics sono stati riconosciuti da importanti agenzie di rating, ricevendo riconoscimenti come un 'AAA' rating da MSCI ESG Ratings, una Medaglia Platinum da EcoVadis e inclusione in vari prestigiosi indici ESG.
WuXi Biologics (2269.HK) ha recibido un Premio Platinum de los Asset ESG Corporate Awards por cuarto año consecutivo. Este prestigioso honor reconoce el compromiso de la empresa con prácticas sostenibles y su enfoque efectivo para impulsar innovación y eficiencia a través de la tecnología verde.
The Asset evalúa a las empresas en varias métricas ESG, incluyendo gobernanza corporativa, financiamiento sostenible, códigos de conducta de proveedores, consumo de energía, emisiones de gases de efecto invernadero y gestión de residuos y agua. WuXi Biologics es la única empresa del sector salud entre los ganadores de este año.
La empresa ha logrado avances significativos en la búsqueda de un desarrollo sostenible y políticas socialmente responsables, alineándose con los Objetivos de Desarrollo Sostenible de las Naciones Unidas. WuXi Biologics es signataria del Pacto Global de la ONU y de la carta de compromiso de la iniciativa Science Based Targets (SBTi).
Los esfuerzos ESG de WuXi Biologics han sido reconocidos por importantes agencias de calificación, recibiendo elogios como un 'AAA' rating de MSCI ESG Ratings, una Medalla Platinum de EcoVadis y su inclusión en varios índices ESG prestigiosos.
우시 바이오로직스 (2269.HK)는 4년 연속으로 자산 ESG 기업 시상식에서 플래티넘 어워드를 수상했습니다. 이 권위 있는 상은 회사의 지속 가능한 관행에 대한 헌신과 친환경 기술을 통한 혁신과 효율성 추진에 대한 효과적인 접근 방식을 인정합니다.
자산은 기업의 지배구조, 지속 가능한 금융, 공급업체 행동 강령, 에너지 소비, 온실가스 배출 및 폐기물과 물 관리 등 다양한 ESG 지표를 평가합니다. 우시 바이오로직스는 올해 수상자 중 유일한 의료 산업 기업입니다.
회사는 지속 가능한 개발과 사회적 책임 정책을 추진하면서 유엔 지속 가능한 개발 목표와 일치하는 중요한 진전을 이루었습니다. 우시 바이오로직스는 유엔 글로벌 컴팩트와 과학 기반 목표(Science Based Targets Initiative, SBTi) 이행에 관한 서신의 서명자입니다.
우시 바이오로직스의 ESG 노력은 주요 평가지의 인정받아, MSCI ESG 평가에서 'AAA' 등급, 에코바디스에서 플래티넘 메달을 획득했으며, 여러 권위 있는 ESG 지수에 포함되었습니다.
WuXi Biologics (2269.HK) a reçu un Prix Platinum des Asset ESG Corporate Awards pour le quatrième année consécutive. Cet honneur prestigieux reconnaît l'engagement de l'entreprise envers des pratiques durables et son approche efficace pour stimuler l'innovation et l'efficacité par le biais de technologies écologiques.
The Asset évalue les entreprises selon divers critères ESG, notamment la gouvernance d'entreprise, le financement durable, les codes de conduite des fournisseurs, la consommation d'énergie, les émissions de gaz à effet de serre et la gestion des déchets et de l'eau. WuXi Biologics est la seule entreprise du secteur de la santé parmi les lauréats de cette année.
L'entreprise a réalisé des progrès significatifs dans la poursuite du développement durable et des politiques socialement responsables, en s'alignant sur les Objectifs de Développement Durable des Nations Unies. WuXi Biologics est signataire du Pacte Mondial des Nations Unies et de la lettre d'engagement de l'initiative Science Based Targets (SBTi).
Les efforts ESG de WuXi Biologics ont été reconnus par des agences de notation majeures, obtenant des distinctions telles qu'un rating 'AAA' des MSCI ESG Ratings, une Médaille Platinum d'EcoVadis, et l'inclusion dans divers indices ESG prestigieux.
WuXi Biologics (2269.HK) hat zum vierten Mal in Folge einen Platinum Award von den Asset ESG Corporate Awards erhalten. Diese prestigeträchtige Auszeichnung erkennt das Engagement des Unternehmens für nachhaltige Praktiken und seinen effektiven Ansatz zur Förderung von Innovation und Effizienz durch grüne Technologie an.
The Asset bewertet Unternehmen anhand verschiedener ESG-Kriterien, einschließlich Unternehmensführung, nachhaltige Finanzierung, Verhaltenskodizes für Anbieter, Energieverbrauch, Treibhausgasemissionen sowie Abfall- und Wassermanagement. WuXi Biologics ist das einzige Unternehmen aus der Gesundheitsbranche unter den diesjährigen Preisträgern.
Das Unternehmen hat bedeutende Fortschritte bei der Verfolgung von nachhaltiger Entwicklung und sozial verantwortlichen Politiken erzielt und stimmt mit den Vereinten Nationen Zielen für nachhaltige Entwicklung überein. WuXi Biologics ist Unterzeichner des UN Global Compact und der Verpflichtungserklärung der Science Based Targets Initiative (SBTi).
Die ESG-Bemühungen von WuXi Biologics wurden von führenden Rating-Agenturen anerkannt, darunter ein 'AAA' Rating von MSCI ESG Ratings, eine Platinmedaille von EcoVadis sowie die Aufnahme in verschiedene angesehene ESG-Indizes.
- None.
- None.
As a widely recognized business news and research organization, The Asset evaluates companies regarding their ESG responsibilities for its annual ESG Corporate Awards, reviewing a wide range of metrics, including corporate governance, sustainability financing, supplier codes of conduct, energy consumption and GHG emissions, and waste and water management. WuXi Biologics is the only company in the healthcare industry among this year's winners.
Dr. Chris Chen, WuXi Biologics' CEO and Chairman of the ESG Committee, commented, "We are profoundly pleased to win the Platinum Award for the fourth consecutive year. While we view the award as a celebration of WuXi Biologics' sustainability achievements over the past years, we also see it as an impetus for us to persist further in our sustainability efforts, pushing the boundaries and demonstrating our leadership in the biologics CRDMO industry for a greener and healthier future."
In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making significant progress in pursuing sustainable development and socially responsible policy initiatives. Demonstrating its commitment, the company is a signatory to the United Nations Global Compact, as well as the global Science Based Targets initiative (SBTi) commitment letter.
The company's efforts have been recognized by major ESG rating agencies. It was granted an "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis; included in the DJSI World Index and Emerging Markets Index; named to the MSCI ESG Leaders Indexes; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; named a Constituent of the FTSE4Good Index Series; and included in the Hang Seng ESG 50 Index.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-receives-esg-corporate-platinum-award-from-the-asset-for-fourth-consecutive-year-302277739.html
SOURCE WuXi Biologics
FAQ
What award did WuXi Biologics (WXXWY) receive in 2024?
How many times has WuXi Biologics (WXXWY) won the Platinum Award from The Asset?
What global initiatives has WuXi Biologics (WXXWY) signed?
What ESG rating did WuXi Biologics (WXXWY) receive from MSCI?
Is WuXi Biologics (WXXWY) included in any ESG indexes?
